Whole genome sequencing has improved the resolution of subtyping of both stx1 and stx2, which supported additional risk assessment as certain stx subtypes, particularly stx2, are more likely to lead to HUS (Friedrich et al., 2002; Orth et al., 2007). This evidence concerns the gene STX2 and hemolytic-uremic syndrome.